an ioxidan s
A icle
Plasma ic Oxida i e and Me abonomic P o ile o Pa ien s wi h
Di e en Deg ees o Bilia y Acu e Panc ea i is Se e i y
Ped o Sil a-Vaz 1,2,3,4,* , I ana Ja ak 5, Luís Ra o 6, Ped o F. Oli ei a 7, Sa a Mo gado-Nunes 4,8 ,
Aida Paulino 2,3,4, Miguel Cas elo-B anco 1,3,4 , Ma ia Filomena Bo elho 9,10,11,12 ,
JoséGuilhe me T alhão9,10,11,12,13, Ma co G. Al es 14 and Ana Ma ga ida Ab an es 9,10,11,12


Ci a ion: Sil a-Vaz, P.; Ja ak, I.; Ra o,
L.; Oli ei a, P.F.; Mo gado-Nunes, S.;
Paulino, A.; Cas elo-B anco, M.;
Bo elho, M.F.; T alhão, J.G.; Al es,
M.G.; e al. Plasma ic Oxida i e and
Me abonomic P o ile o Pa ien s wi h
Di e en Deg ees o Bilia y Acu e
Panc ea i is Se e i y. An ioxidan s
2021,10, 988. h ps://doi.o g/
10.3390/an iox10060988
Academic Edi o : Joseph Cullen
Recei ed: 16 May 2021
Accep ed: 15 June 2021
Published: 21 June 2021
Publishe ’s No e: MDPI s ays neu al
wi h ega d o ju isdic ional claims in
published maps and ins i u ional a il-
ia ions.
Copy igh : © 2021 by he au ho s.
Licensee MDPI, Basel, Swi ze land.
This a icle is an open access a icle
dis ibu ed unde he e ms and
condi ions o he C ea i e Commons
A ibu ion (CC BY) license (h ps://
c ea i ecommons.o g/licenses/by/
4.0/).
1Heal h Sciences Resea ch Cen e, Uni e si y o Bei a In e io (CICS-UBI), 6200-506 Co ilhã, Po ugal;
[email p o ec ed]
2Gene al Su ge y Depa men , Hospi al Ama o Lusi ano, Unidade Local de Saúde de Cas elo B anco,
6000-085 Cas elo B anco, Po ugal; [email p o ec ed]
3Facul y o Heal h Sciences, Uni e si y o Bei a In e io , 6200-506 Co ilhã, Po ugal
4Clinical Academic Cen e o Bei as (CACB), 6200-506 Co ilhã, Po ugal; [email p o ec ed]
5Depa men o Pha maceu ical Technology, Facul y o Pha macy, Uni e si y o Coimb a,
3000-548 Coimb a, Po ugal; [email p o ec ed]
6Heal h School o he Poly echnic o Gua da, 6300-559 Gua da, Po ugal; [email p o ec ed]
7QOPNA & LAQV, Depa men o Chemis y, Uni e si y o A ei o, 3810-193 A ei o, Po ugal;
[email p o ec ed]
8Poly echnic Ins i u e o Cas elo B anco, Escola Supe io de Ges ão, 6000-084 Cas elo B anco, Po ugal
9Biophysics Ins i u e, Facul y o Medicina, Uni e si y o Coimb a, 3000-548 Coimb a, Po ugal;
[email p o ec ed] (M.F.B.); [email p o ec ed] (J.G.T.); [email p o ec ed] (A.M.A.)
10 Coimb a Ins i u e o Clinical and Biomedical Resea ch (iCBR) A ea o En i onmen Gene ics and
Oncobiology (CIMAGO), Facul y o Medicina, Uni e si y o Coimb a, 3000-548 Coimb a, Po ugal
11 CNC.IBILI Conso ium/Cen e o Inno a ion Biomedicine and Bio echnology (CIBB),
Uni e si y o Coimb a, 3000-548 Coimb a, Po ugal
12 Clinical Academic Cen e o Coimb a (CACC), 3000-561 Coimb a, Po ugal
13 Su ge y Depa men , Cen o Hospi ala e Uni e si á io de Coimb a (CHUC), Facul y o Medicina,
Uni e si y Hospi al, 3000-075 Coimb a, Po ugal
14 Depa men o Ana omy and Uni o Mul idisciplina y Resea ch in Biomedicine (UMIB),
Ins i u e o Biomedical Sciences Abel Salaza (ICBAS), Uni e si y o Po o, 4050-313 Po o, Po ugal;
[email p o ec ed]
*Co espondence: [email p o ec ed]; Tel.: +351-966-498-337
Abs ac :
Acu e panc ea i is (AP) is an in lamma o y p ocess o he panc eas wi h a iable in ol e-
men o he panc ea ic and pe ipanc ea ic issues and emo e o gan sys ems. The main goal o his
s udy was o e alua e he in lamma o y bioma ke s, oxida i e s ess (OS), and plasma me abolome
o pa ien s wi h di e en deg ees o bilia y AP se e i y o imp o e i s p ognosis. Twen y-nine
pa ien s wi h bilia y AP and 11 heal hy con ols we e en olled in his s udy. We analyzed se e al
in lamma o y bioma ke s, mul i ac o ial sco es, eac i e oxygen species (ROS), an ioxidan s de enses,
and he plasma me abolome o bilia y AP and heal hy con ols. Hepcidin (1.00), CRP (0.94), and SIRI
(0.87) we e he mos accu a e se ological bioma ke s o AP se e i y. OS played a pi o al ole in he
ini ial phase o AP, wi h signi ican changes in ROS and an ioxidan de enses ela ing o AP se e i y.
Phenylalanine (p< 0.05), h eonine (p< 0.05), and lipids (p< 0.01) showed signi ican changes in
AP se e i y. The ole o hepcidin and SIRI we e con i med as new p ognos ic bioma ke s o bilia y
AP. OS appea s o ha e a ole in he onse and p og ession o he AP p ocess. O e all, his s udy
iden i ied se e al me aboli es ha may p edic he onse and p og ession o bilia y AP se e i y,
cons i u ing he i s me abonomic s udy in he ield o bilia y AP.
Keywo ds:
acu e bilia y panc ea i is; in lamma ion; p ognos ic; se e i y; hepcidin; sys emic in lam-
ma o y esponse index; oxida i e s ess; me abonomics
An ioxidan s 2021,10, 988. h ps://doi.o g/10.3390/an iox10060988 h ps://www.mdpi.com/jou nal/an ioxidan s
An ioxidan s 2021,10, 988 2 o 18
1. In oduc ion
Acu e panc ea i is (AP) is an in lamma o y diso de o he exoc ine panc eas wi h
high mo bidi y and mo ali y i associa ed wi h local and sys emic complica ions [
1
,
2
].
Mos pa ien s p esen wi h mild sel -limi ed AP wi h a good p ognosis [
3
]. Howe e ,
15–20% p og ess o a se e e AP wi h panc ea ic nec osis and high mo bidi y and mo ali y
associa ed wi h sys emic in lamma o y esponse synd ome (SIRS) and mul iple o gan
ailu e [
4
,
5
]. The e has been an inc easing incidence in he las decades, al hough wi h an
unchanged mo ali y a e [
6
]. The o e all mo ali y o AP is less han 5%, hough se e e
AP is associa ed wi h a mo ali y up o 30–50% [
1
,
7
]. The mos common causes o AP a e
galls ones and alcohol [
6
]. In he Medi e anean and o he sou he n Eu opean coun ies,
including Po ugal, galls ones a e he dominan e iology [8].
Se e al heo ies associa ed wi h he ea ly pa hogenesis o AP ha e been desc ibed,
such as he in a-acina and duc al ac i a ion o p o eoly ic enzymes, leukocy e chemo axis,
he elease o p o- and an i-in lamma o y cy okines, oxida i e s ess (OS), mi ochond ial
dys unc ion, galls one mig a ion, mic oci cula ion inju y, as well as bac e ial ansloca ion
o he panc eas and sys emic ci cula ion [
9
,
10
]. Ne e heless, he molecula mechanisms
by which hose e ec s a e media ed emain unknown.
AP is associa ed wi h a high a iabili y o se e i y, and al hough an ea ly iden i ica ion
o pa ien s who will de elop se e e AP is c ucial, his iden i ica ion emains a g ea
challenge. De e mina ion o AP p ognosis is c ucial o op imize he ini ial he apeu ic
app oach and dec ease mo ali y. Se e al se ological bioma ke s and sco es ha e been
desc ibed, namely C- eac i e p o ein (CRP) [
11
], hepcidin [
12
,
13
], p ocalci onin (PCT) [
14
],
he sys emic in lamma o y esponse index (SIRI) [
13
], he bedside index o se e i y in
acu e panc ea i is (BISAP) [15], SIRS [16], and he modi ied Ma shall sco e (MMS) [17].
The ole o eac i e oxygen species (ROS) in he pa hophysiology o AP has been
demons a ed [
18
,
19
] and occu s in he ea ly s ages o his in lamma o y p ocess [
20
].
Howe e , i is no clea whe he ROS ac as media o s o ini ia e he complex cascade ha
leads o AP and, hus, he exac ole o OS in he de elopmen o AP emains unclea [
21
].
OS is p esen ly conside ed a c i ical media o o he ea ly local e en s ela ed o AP and he
associa ed SIRS [
22
]. Mi ochond ia a e suscep ible o OS, and mi ochond ial dys unc ion
is o en used as a speci ic bioma ke o oxidan exposu e [
23
]. In expe imen al models
o AP, acina cells we e shown o die h ough nec osis and apop osis, pa hways linked
o mi ochond ial dys unc ion [
24
]. O he s sugges ha mi ochond ial dys unc ion is
associa ed wi h sys emic in lamma o y p ocesses [
25
], bu he mechanisms emain la gely
unknown. Thus, OS-associa ed e en s and bioma ke s in AP emain o be de ined.
The de e mina ion o me aboli e changes ha desc ibe a biological pheno ype based
on
1
H nuclea magne ic esonance (NMR) spec oscopy has been widely applied o de-
ine p ognos ic bio luid p o iles o physiological o pa hological s a es [
26
]. In in lam-
ma o y diso de s, such as AP, only a ew s udies o me abolome ha e been epo ed.
Villaseño e al. [
27
] s udied he me abolic pheno ype in u ine and plasma samples o
15 pa ien s wi h AP. The e iologies o he AP g oup we e galls ones (6/15) and alcohol
(9/15). They ound changes in alanine, aline, and hippu a e in pa ien s wi h AP and
concluded ha hese me aboli es ha e he po en ial o se e as diagnos ic ools. Lusczek
e al. [
28
] e alua ed he po en ial o u ina y
1
H-NMR me abonomics in he diagnosis o
AP. The au ho s analyzed i e pa ien s wi h AP and concluded ha i is possible o ob ain
a dis inc me abolome in AP pa ien s’ u ine samples compa ed o heal hy con ols. Tha
s udy iden i ied ci a e as he p ima y me aboli e associa ed wi h he in lamma o y AP
s a e and alcohol consump ion. Xu e al. [
29
] s udied he se um me abolomics o mild AP
in 38 pa ien s. Al hough he au ho s did no speci y he e iology o AP pa ien s, by using
he ch oma og aphy-high- esolu ion mass spec ome y (UPLC-HRMS) echnique, hey
iden i ied decanyl choline, dodecanol, and 2- e adecanone as diagnosis me aboli es, and
sphinganine, L- hy onine, glycocholic acid and 2- e adecanone as he apeu ic esponse
me aboli es. Xiao e al. [
30
], using gas-ch oma og aphy/mass spec ome y (GS-MS), iden-
i ied se e al me aboli es, such as 3-hyd oxubu y ic, D-glucose, and hexadecenoic acid,
An ioxidan s 2021,10, 988 3 o 18
wi h po en ial clinical ele ance o diagnosis in 40 pa ien s wi h AP. I was sugges ed
3-hyd oxybu y ic acid and ci ic acid ha e a p ognosis alue. Huang e al. [
31
] s udied
h ee AP e iologies (29 pa ien s wi h hype lipidemia, 20 wi h alcoholic AP, and 27 wi h
bilia y AP). They concluded ha L- y osine, oc adecanoic acid, choles e ol, glyce ol 1-
hexadecanoa e, and L-lac ic acid a e me aboli es wi h po en ial diagnosis ele ance and
(R)-3-hyd oxybu y ic acid and manni ol could dis inguished AP om he heal hy g oup.
Howe e , his s udy did no e alua e he cha ac e is ics be ween each g oup o AP pa ien s,
no was he p ognosis o AP se e i y aken in o accoun . These i e pape s desc ibed se -
e al me aboli es, mainly as diagnos ic ools, bu only one speci ically s udied he subg oup
o pa ien s wi h bilia y AP, compa ing i wi h o he AP e iologies.
This s udy aimed o e alua e he pa hophysiology o AP by analyzing he in lam-
ma o y bioma ke s and mul i ac o ial sco es, OS, and plasma me abolome o bilia y AP
pa ien s and heal hy con ols. I is in ended o con ibu e o a be e unde s anding o
bilia y AP’s pa hophysiology and hus imp o e p ognosis.
2. Ma e ials and Me hods
2.1. Pa icipan s
S udy pa icipan s we e ec ui ed among pa ien s wi h bilia y AP admi ed o he
Depa men o Gene al Su ge y o he Hospi al Ama o Lusi ano o Unidade Local de Saúde
de Cas elo B anco, Uni e si y Teaching Hospi al, Cas elo B anco, Po ugal. Twen y-nine
pa ien s and 11 heal hy con ols we e conside ed o he s udy. The s udy p o ocol was
app o ed by he local e hics commi ee ( e e ence numbe 10294/15) and was conduc ed
in compliance wi h he Decla a ion o Helsinki. Signed in o med consen was ob ained
om all pa icipan s.
2.2. S udy Design
Subjec s wi h AP ha accep ed he eques o pa icipa e and me he eligibili y c i e ia
o admission we e ec ui ed be ween No embe 2015 and Janua y 2016. AP was de ined
acco ding o he e ised A lan a classi ica ion (RAC). A leas wo o he ollowing h ee
ea u es mus ha e been p esen : (1) abdominal pain consis en wi h AP; (2) se um lipase
ac i i y (o amylase ac i i y) a leas h ee imes g ea e han he uppe limi o a no mal
alue; (3) and cha ac e is ics indings o AP on con as -enhanced compu ed omog aphy
(CECT) and less commonly on magne ic esonance imaging (MRI) o ansabdominal
ul asonog aphy (US) [17].
All adul pa ien s (
≥
18 yea s old) wi h bilia y AP we e included. Pa ien s wi h
o he causes o AP excep bilia y, ecu en AP, ch onic panc ea i is, panc ea i is due o
malignancy, p egnan pa ien s, pa ien s wi h ime om onse o disease o p esen a ion in
he eme gency oom g ea e han 24 h, and pa ien s being hospi alized o mo e han 24 h
a he ime o ec ui men we e excluded. Fo an e iological con i ma ion o AP, he pa ien s
unde wen US wi h iden i ica ion o galls ones o mic oli hiasis. A e he US, pa ien s
wi h e iological doub unde wen endoscopic ul asonog aphy o exclude mic oli hiasis
and cha ac e ize he bilia y ee.
Local and sys emic complica ions we e de ined acco ding o he RAC [
17
]. The se e i y
o AP was de ined acco ding o he RAC: mild (no o gan ailu e o no local o sys emic
complica ions), mode a ely se e e (o gan ailu e ha esol es wi hin 48 h and he p esen
local o sys emic complica ions o bo h wi hou pe sis en o gan ailu e), and se e e
(p esence o pe sis en o gan ailu e o SIRS). O e all, his s udy included 40 indi iduals:
mild (n= 10), mode a ely se e e (n= 9), and se e e (n= 10) AP pa ien s and heal hy
con ols (n= 11).
All subjec s included in his s udy we e e alua ed o como bidi ies by applying
he Cha lson como bidi y index (CCI). This index is he mos equen ly used ool o
measu e co-exis ing diseases and i has been alida ed o p edic ing he isk o mo ali y,
disabili y, hospi aliza ion, and leng h o hospi al s ay in se e al clinical se ings [
32
]. CCI is
An ioxidan s 2021,10, 988 4 o 18
age-dependen and e alua es se e al pa hological condi ions, including ca dio ascula ,
espi a o y, li e , and pep ic diseases as well as diabe es and AIDS [33].
2.3. Analysis o Bioma ke s and Sco es Sys ems
Blood samples we e collec ed om each pa ien ha had been as ing o a leas 6 h
on admission and a e 48 h o onse o symp oms, d awn in o 5 mL hepa in- ea ed ubes
and cen i uged o 10 min a 1500
×
g. The plasma was hen collec ed and s o ed a
−
80
◦
C
un il analysis. Lipase (U/L), amylase (U/L), CRP (mg/dL9, PCT (ng/dL), whi e blood cells
(WBC, 10
3
/
µ
L), neu ophil (N, 10
3
/
µ
L), lymphocy e (L, 10
3
/
µ
L), monocy e (M, 10
3
/
µ
L),
calcium (mg/dL), albumin (g/dL), o al p o eins (g/dL), and hepcidin (ng/mL) we e
analyzed ollowing ce i ied analysis a he Depa men o Clinical Pa hology, Hospi al
Ama o Lusi ano o he Unidade Local de Saúde de Cas elo B anco. Neu ophil/lymphocy e
(N/L) a io and SIRI we e calcula ed.
The BISAP sco e was desc ibed in 2008 and consis s o a simple, ea ly assessmen o
mo ali y isk in pa ien s wi h AP. I e alua ed i e pa ame e s: blood u ea ni ogen (BUN),
men al s a us, SIRS, age, and pleu al e usion. The cu -o used o assess he mo ali y
isk and se e i y o AP was
≥
3. SIRS is a simple and widely used sco e in a clinical
se ing. I e alua es ou pa ame e s: empe a u e, espi a o y a e, pulse, and WBCs. This
sco e is de ined by he p esence o
≥
2 o he desc ibed pa ame e s. The MMS allows o
he assessmen o mul io gan ailu e in AP. O gan ailu es includes one o mo e o he
ollowing pa ame e s: ca dio ascula , espi a o y, and kidney ailu e. Mul io gan ailu e is
p esen o a cu -o o
≥
2. In he p esen s udy, all h ee sco es we e assessed on admission
and 48 h a e onse o symp oms.
2.4. Oxida i e S ess E alua ion
Ca bonyl g oups, p o ein ni a ion, and lipid pe oxida ion a e usually used as bioma k-
e s o OS- ela ed al e a ions in p o eins and lipids. We e alua ed, on admission: 2,4-
dini ophenyl (2,4-DNP), 3-ni o y osine (3-NO), and 4-hyd oxynonenal (4-HNE), espec-
i ely. The con en o hese adduc s in plasma samples was e alua ed using speci ic
an ibodies ia slo -blo as p e iously desc ibed [
34
,
35
]. The ac i i y o se e al an ioxidan
de ense enzymes was also e alua ed, namely glu a hione pe oxidase (GPx), glu a hione
educ ase (GR), supe oxide dismu ase (SOD), and ca alase (CAT). GPx and GR concen a-
ions in plasma samples we e de e mined using p e iously desc ibed me hods [
36
]. The
assay o SOD ac i i y was based on he eac ion in which SOD educes he supe oxide
anion o hyd ogen pe oxide and oxygen, using a me hod p e iously desc ibed [
37
]. The
CAT ac i i y assay was based on he measu emen o hyd ogen pe oxide p oduced by he
ac ion o CAT.
2.5. P o on NMR (1H-NMR) Spec oscopy
1
H-NMR spec a o plasma samples we e acqui ed and quan i ied as p e iously
desc ibed [
38
]. Sodium uma a e ( inal concen a ion o 1 mM) was used as an in e nal
e e ence (6.50 ppm) o quan i y he ollowing me aboli es p esen in plasma samples media
(mul iple , ppm). Rela i e a eas o
1
h-NMR esonances and me aboli es concen a ions
we e quan i ied as p e iously desc ibed [
38
]. In b ie , plasma samples composed o
pa ien s wi h bilia y AP, collec ed on admission, and heal hy subjec s o he con ol
g oup we e analyzed. These samples we e hawed, homogenized using a o ex, and
cen i uged (9200 pm, 5 min). NMR spec a we e acqui ed on a Va ian Ino a 600 MHz
(14.1 T) spec ome e equipped wi h a 3 mm QXI p obe wi h a z-wa e p esa u a ion. Wa e
sa u a ion equencies we e op imized o each sample. Chemical shi s we e in e nally
e e enced o a glucose double a 5.23 ppm. Me aboli e assignmen was based on a
compa ison wi h p e iously published da a and e e ence spec a a ailable in public
da abases such as HMBD [
39
]. Addi ionally, 2D homonuclea TOCSY spec a we e eco ded
o help wi h spec al assignmen [40].
An ioxidan s 2021,10, 988 5 o 18
Da a ma ices o mul i a ia e analysis we e c ea ed in AMIX-Viewe ( e sion 3.9.15,
B uke Biospin, Rheins e en) using all in ensi y alues in he 0.75–8.5 ppm egion wi h he
exclusion o wa e and uma a e egions as well as he egions wi hou signal. P ocessed
spec a we e aligned o minimize shi a ia ions [
41
] and no malized by in eg al a ea
o accoun o ma ix dilu ion e ec s and expe imen al condi ions [
42
]. Mul i a ia e
analysis was pe o med in Simca 14 (Ume ics, Umea, Sweden) on uni - a iance scaled da a
ma ices. P incipal componen analysis (PCA) e alua ed he ini ial da a s uc u e, ollowed
by pa ial leas squa es disc iminan analysis (PLS-DA) o iden i y me aboli e con ibu ion
o class sepa a ion. PLS-DA loadings we e calcula ed by mul iplying he a iable weigh s
(w) wi h he espec i e s anda d de ia ions and colo -coded acco ding o he size o a iable
impo ance o p ojec ion alues (VIP). Me aboli es wi h VIP > 1 we e conside ed ele an o
g oup sepa a ion. De aul se en old c oss- alida ion and pe mu a ion es s [
43
] we e used
o alida e he obse ed a ia ion (R
2
) and p edic i e po en ial (Q
2
) o PLS-DA models.
Addi ionally, well- esol ed peaks o ele an me aboli es we e in eg a ed (AMIX-Viewe ,
e sion 3.9.15, B uke Biospin, Rheins e en) and no malized by in eg al a eas. Biological
e ec s o no malized a eas we e es ima ed by calcula ing e ec size. Addi ionally, hey
we e analyzed ia wo-way ANOVA ollowed by Tukey’s pos hoc es (G aph-Pad P ism 6
o Windows, G aph Pad So wa e, La Jolla, Cali o nia, USA, www.g aphpad.com, accessed
on 15 Decembe 2020).
2.6. S a is ical Analysis
Resul s a e exp essed in mean (SD)
±
s anda d e o o he mean (SEM), median
(Q1, Q3), o n (%). No mali y was assessed using he Shapi o–Wilk es . Rega ding he
quan i a i e a iables, he cen al endency was compa ed using S uden ’s o Mann–
Whi ney es s (2 ca ego ies) o ANOVA o he K uskal–Wallis es (>2 ca ego ies). In
quali a i e a iables, associa ions we e e i ied using he Chi-squa ed es , wi h Fishe ’s
co ec ion when necessa y. Recei e ope a ing cha ac e is ics (ROC) cu es we e calcula ed
o assess he p ognos ic accu acy and de e mine he bes cu -o poin s. A p< 0.05 indica ed
s a is ical signi icance. S a is ical analysis was pe o med using SPSS 25.0 (SPSS, Chicago,
IL, USA).
3. Resul s
3.1. Clinical Da a
The baseline cha ac e is ics o heal hy con ols (n= 11) and bilia y AP pa ien s: mild
AP (n= 19), mode a ely se e e AP (n= 9), and se e e AP (n= 10) a e shown in Table 1.
The e we e no signi ican di e ences in he demog aphic ea u es be ween he con ol
g oup and bilia y AP pa ien s. The e we e also no di e ences be ween he demog aphic
cha ac e is ics in he h ee deg ees o AP se e i y, as exp essed in Table 1.
Table 1.
Baseline cha ac e is ics o heal hy con ols and bilia y AP pa ien s included in he s udy. (
‡
Mann–Whi ney es ;
‡‡ Chi-squa ed es ; ‡‡‡ K uskal–Wallis es ).
Con ol
(n= 11)
Sample
(n= 29) pMild AP
(n= 10)
Mode a ely Se e e AP
(n= 9)
Se e e AP
(n= 10) p
Age (yea s) 69 ±14.6 65 ±18.9 0.65 ‡54 ±16.8 69 ±17.2 73 ±18.7 0.53 ‡‡‡
Female sex 6 (54.5%) 20 (69%) 0.41 ‡‡ 8 (80%) 6 (66.7%) 6 (60%) 0.39 ‡‡
BMI (kg/m2)26.7 ±3.0 26.7 ±3.8 0.98 ‡27.0 ±2.9 26.4 ±4.6 26.6 ±4.0 0.92 ‡‡‡
BMI ≥30 kg/m22 (18.2%) 6 (20.7%) 0.91 ‡‡ 2 (20%) 2 (22.2%) 2 (20%) 0.91 ‡‡
CCI 3 (1–4) 3 (1–4) 0.49 ‡1 (0–2) 3 (2–4) 3 (1–4) 0.49 ‡‡‡
Hospi al s ay (days) 12 ±7.8 - 6 ±2.5 11 ±5.0 18 ±8.7 -
Mo ali y 3 (10.3%) 3 (30%)
AP: acu e panc ea i is; BMI: body mass index; CCI: Cha lson como bidi ies index.
Se e al biochemical ma ke s and mul i ac o ial sco es we e assessed, bo h on admis-
sion and 48 h a e onse o symp oms, which a e exp essed in Table 2.

An ioxidan s 2021,10, 988 6 o 18
Table 2.
Se e al biochemical ma ke s and mul i ac o ial sco es o heal hy con ols and bilia y AP pa ien s included in he
s udy. (‡K uskal–Wallis es ).
Con ols
(n= 11) Time Sample
(n= 29)
Mild AP
(n= 10)
Mode a ely Se e e AP
(n= 9)
Se e e AP
(n= 10) p‡
WBC 6.5 ±1.6 Admission 14.5 ±5.4 11.2 ±4.5 15.0 ±5.6 17.4 ±4.1 0.017
48 h 12.1 ±6.3 6.9 ±3.5 12.7 ±7.5 14.9 ±2.8 0.002
Neu ophils 4.8 ±0.9 Admission 12.4 ±5.5 8.6 ±4.5 13.2 ±5.3 15.7 ±3.6 0.011
48 h 10.0 ±6.2 4.7 ±3.2 10.4 ±6.9 13.2 ±2.7 0.001
SIRI Aission 7.4 ±6.3 3.6 ±3.9 8.8 ±7.5 11.4 ±4.9 0.022
48 h 6.6 ±6.4 1.6 ±2.3 5.9 ±6.4 10.6 ±5.7 0.001
PCT Admission 2.9 ±6.9 0.7 ±0.9 4.5 ±5.8 5.9 ±10.9 0.001
48 h 4.1 ±7.3 0.6 ±0.1 6.6 ±9.1 7.9 ±8.8
<0.001
CRP 5.3 ±1.1 Admission 42.8 ±82.7 5.4 ±1.2 33.0 ±51.5 88.9 ±22.0 0.032
48 h 170.7 ±152.6 15.9 ±14.0 180.6 ±107.2 316.6 ±107.9
<0.001
Hepcidin Admission 64.2 ±69.6 20.4 ±12.2 69.9 ±37.9 100.7 ±90.5 0.047
48 h 136.7 ±138.7 26.4 ±27.2 56.6 ±51.9 286.7 ±87.3
<0.001
Calcium Admission 9.0 ±0.6 8.9 ±0.5 9.1 ±0.4 8.9 ±0.9 NS
48 h 8.5 ±0.8 8.9 ±0.3 8.7 ±0.5 7.9 ±1.0 0.014
Albumin Admission 3.7 ±0.5 3.8 ±0.4 3.7 ±0.4 3.5 ±0.5 NS
48 h 3.1 ±0.5 3.5 ±0.3 3.2 ±0.3 2.7 ±0.6 0.001
To al p o eins
Admission 6.5 ±0.6 6.7 ±0.5 6.7 ±0.5 6.3 ±0.6 NS
48 h 5.9 ±0.6 6.4 ±0.4 6.0 ±0.3 5.3 ±0.6 0.001
BISAP Admission 1 (1–3) 1 (0–1) 1 (1–2) 3 (2–3)
<0.001
48 h 2 (1–4) 1 (0–1) 1 (1–3) 4 (4–5)
<0.001
SIRS Admission 1 (1–2) 1 (0–1) 2 (1–2) 2 (1–2) 0.045
48 h 1 (0–2) 0 (0–1) 1 (0–2) 3 (2–3) 0.001
MMS Admission 0 (0–1) 0 (0–0) 0 (0–2) 1 (0–2) 0.017
48 h 0 (0–2) 0 (0–0) 0 (0–2) 3 (2–3)
<0.001
AP: acu e panc ea i is; BISAP: bedside index o se e i y in acu e panc ea i is; BMI: body mass index; CRP: C- eac i e p o ein; NS: no
signi ican ; MMS: modi ied Ma shall sco e; SIRS: sys emic in lamma o y esponse synd ome; WBC: whi e blood cells.
Th ough he analysis o Table 2, bo h on admission and 48 h a e onse o symp oms,
all se ological bioma ke s excep calcium (p= 0.82), albumin (p= 0.21), and o al p o eins
(p= 0.34) on admission show signi ican changes be ween he di e en deg ees o AP
se e i y. All he mul i ac o ial sco es show signi ican changes be ween he deg ees o
se e i y o AP.
On admission, PCT (0.83), BISAP (0.83), and SIRI (0.82) had he highes p edic i e
alues o se e e AP. Rega ding mo ali y, BISAP (0.95), SIRI (0.85), and PCR (0.85) had he
highes p edic i e alues. Fo y-eigh hou s a e onse o symp oms, o se e e AP, he
se ological ma ke wi h he mos signi ican p edic i e powe was hepcidin (1.00) ollowed
by BISAP (0.98), CRP (0.94), and SIRI (0.87). When analyzing he p edic i e powe ela ed
o mo ali y, BISAP (0.94) was ound o ha e he highes p edic i e alue ollowed by
hepcidin (0.90), CRP (0.88), and SIRI (0.86) as ep esen ed in Figu e 1.
3.2. Pa ien s wi h Bilia y AP P esen ed Inc eased Le els o Plasma OS-Rela ed Ma ke s and Lowe
CAT and SOD Ac i i ies Than Heal hy Subjec s and Inc eased Le els o Lipid Pe oxida ion and
Lowe Le els o CAT and SOD in Se e e Bilia y AP
As ep esen ed in Figu e 2A, a signi ican inc ease on admission was e i ied ela ed
o he le els o lipid pe oxida ion (p< 0.05), p o ein ni a ion (p< 0.001), and p o ein
ca bonyla ion (p< 0.05) in AP pa ien s when compa ed wi h heal hy indi iduals. In
addi ion, as shown in Figu e 2B, he e was a signi ican inc ease in lipid pe oxida ion when
compa ed o mild and se e e AP (p< 0.05) and mode a ely se e e and se e e AP (p< 0.05).
A endency o inc eased p o ein ni a ion le els in se e e AP and in se e e o ms o AP in
p o ein ca bonyla ion, al hough wi hou s a is ical signi icance, was also demons a ed.
An ioxidan s 2021,10, 988 7 o 18
An ioxidan s 2021, 10, x FOR PEER REVIEW 7 o 19
Figu e 1. Recei e ope a ing cha ac e is ics (ROC) cu es o de e mining he cu -o alues o WBC,
SIRI, PCT, CRP, hepcidin, BISAP, SIRS, and MMS o (a) se e e AP and (b) mo ali y on admission
and (c) se e e AP and (d) mo ali y 48 h a e onse o symp oms. AP: acu e panc ea i is; BISAP:
bedside index o se e i y in acu e panc ea i is; BMI: body mass index; CRP: C- eac i e p o ein;
MMS: modi ied Ma shall sco e; SIRS: sys emic in lamma o y esponse synd ome; WBC: whi e
blood cells.
3.2. Pa ien s wi h Bilia y AP P esen ed Inc eased Le els o Plasma OS-Rela ed Ma ke s and
Lowe CAT and SOD Ac i i ies Than Heal hy Subjec s and Inc eased Le els o Lipid
Pe oxida ion and Lowe Le els o CAT and SOD in Se e e Bilia y AP
As ep esen ed in Figu e 2A, a signi ican inc ease on admission was e i ied ela ed
o he le els o lipid pe oxida ion (p < 0.05), p o ein ni a ion (p < 0.001), and p o ein
ca bonyla ion (p < 0.05) in AP pa ien s when compa ed wi h heal hy indi iduals. In
addi ion, as shown in Figu e 2B, he e was a signi ican inc ease in lipid pe oxida ion
when compa ed o mild and se e e AP (p < 0.05) and mode a ely se e e and se e e AP (p
< 0.05). A endency o inc eased p o ein ni a ion le els in se e e AP and in se e e o ms
o AP in p o ein ca bonyla ion, al hough wi hou s a is ical signi icance, was also
demons a ed.
Figu e 1.
Recei e ope a ing cha ac e is ics (ROC) cu es o de e mining he cu -o alues o WBC,
SIRI, PCT, CRP, hepcidin, BISAP, SIRS, and MMS o (
a
) se e e AP and (
b
) mo ali y on admission
and (
c
) se e e AP and (
d
) mo ali y 48 h a e onse o symp oms. AP: acu e panc ea i is; BISAP:
bedside index o se e i y in acu e panc ea i is; BMI: body mass index; CRP: C- eac i e p o ein; MMS:
modi ied Ma shall sco e; SIRS: sys emic in lamma o y esponse synd ome; WBC: whi e blood cells.
An ioxidan s 2021, 10, x FOR PEER REVIEW 8 o 19
Figu e 2. Plasma le els o OS- ela ed ma ke s o acu e panc ea i is (AP) and heal hy con ol g oups.
(A.1) 4-HNE (lipid pe oxida ion), (A.2) 3-NO (p o ein ni a ion), (A.3) DNP (p o ein ca bonyla ion)
in he con ol g oup and bilia y AP pa ien s. (B.1) 4-HNE (lipid pe oxida ion), (B.2) 3-NO (p o ein
ni a ion), (B.3) DNP (p o ein ca bonyla ion) in he di e en deg ees o bilia y AP se e i y on
admission. AP: acu e panc ea i is; 3-NO: 3-ni o y osine; 4-HNE: 4-hyd oxynonenal; DNP: 2,4-
dini ophenyl-hyd azone. Resul s a e exp essed as mean ± SEM. The di e ences e sus con ol
a e ma ked by *, whe e * ep esen s p < 0.05 and *** p < 0.001. Mann–Whi ney es : (A.1–A.3).
Compa ison o Fishe ’s leas signi ican di e ence pos hoc es : (B.1–B.3).
The ac i i y o enzymes ela ed o he an ioxidan sys em such as GR, GPx, CAT, and
SOD we e e alua ed. As shown in Figu e 3A, a endency owa d an inc ease in GR ac i i y
was de ec ed in he plasma o AP pa ien s compa ed o he heal hy con ol indi iduals
bu wi hou s a is ical signi icance. CAT and SOD p esen ed wi h a signi ican dec ease
in AP pa ien s’ ac i i ies compa ed o he heal hy con ol g oup (p < 0.01 and p < 0.001,
espec i ely).
Figu e 2.
Plasma le els o OS- ela ed ma ke s o acu e panc ea i is (AP) and heal hy con ol g oups.
(
A.1
) 4-HNE (lipid pe oxida ion), (
A.2
) 3-NO (p o ein ni a ion), (
A.3
) DNP (p o ein ca bonyla ion)
in he con ol g oup and bilia y AP pa ien s. (
B.1
) 4-HNE (lipid pe oxida ion), (
B.2
) 3-NO (p o ein
ni a ion), (
B.3
) DNP (p o ein ca bonyla ion) in he di e en deg ees o bilia y AP se e i y on
admission. AP: acu e panc ea i is; 3-NO: 3-ni o y osine; 4-HNE: 4-hyd oxynonenal; DNP: 2,4-
dini ophenyl-hyd azone. Resul s a e exp essed as mean
±
SEM. The di e ences e sus con ol
a e ma ked by *, whe e * ep esen s p< 0.05 and *** p< 0.001. Mann–Whi ney es : (
A.1
–
A.3
).
Compa ison o Fishe ’s leas signi ican di e ence pos hoc es : (B.1–B.3).
An ioxidan s 2021,10, 988 8 o 18
The ac i i y o enzymes ela ed o he an ioxidan sys em such as GR, GPx, CAT,
and SOD we e e alua ed. As shown in Figu e 3A, a endency owa d an inc ease in
GR ac i i y was de ec ed in he plasma o AP pa ien s compa ed o he heal hy con ol
indi iduals bu wi hou s a is ical signi icance. CAT and SOD p esen ed wi h a signi ican
dec ease in AP pa ien s’ ac i i ies compa ed o he heal hy con ol g oup (p< 0.01 and
p< 0.001, espec i ely).
An ioxidan s 2021, 10, x FOR PEER REVIEW 9 o 19
Figu e 3. The ac i i y o an ioxidan enzymes in plasma o acu e panc ea i is (AP) and heal hy
con ol g oups. GR: glu a hione educ ase; GPx: glu a hione pe oxidase; CAT: ca alase; SOD:
supe oxide dismu ase om he heal hy con ol g oup and bilia y AP pa ien s (A) and in he
di e en deg ees o bilia y AP pa ien s (B). Resul s a e exp essed as mean ± SEM. The di e ences
e sus con ol a e ma ked by *, whe e * ep esen s p < 0.05, ** p < 0.01 and *** p < 0.001. Mann–
Whi ney es : (A.1–A.4). Compa ison o Fishe ’s leas signi ican di e ence pos hoc es : (B.1–B.4).
Acco ding o he se e i y, as shown in Figu e 3B, when analyzing he ac i i y o he
an ioxidan enzymes in he plasma o pa ien s wi h di e en deg ees, he e was a
s a is ically signi ican dec ease in CAT ac i i y in pa ien s wi h se e e AP compa ed wi h
mild bilia y AP (p < 0.05). Plasma SOD ac i i y was also signi ican ly dec eased when
compa ing pa ien s wi h mild and mode a ely se e e bilia y AP and be ween mild and
se e e bilia y AP pa ien s (p < 0.001, o bo h).
Figu e 3.
The ac i i y o an ioxidan enzymes in plasma o acu e panc ea i is (AP) and heal hy con ol
g oups. GR: glu a hione educ ase; GPx: glu a hione pe oxidase; CAT: ca alase; SOD: supe oxide
dismu ase om he heal hy con ol g oup and bilia y AP pa ien s (
A
) and in he di e en deg ees
o bilia y AP pa ien s (
B
). Resul s a e exp essed as mean
±
SEM. The di e ences e sus con ol a e
ma ked by *, whe e * ep esen s p< 0.05, ** p< 0.01 and *** p< 0.001. Mann–Whi ney es : (
A.1
–
A.4
).
Compa ison o Fishe ’s leas signi ican di e ence pos hoc es : (B.1–B.4).
Acco ding o he se e i y, as shown in Figu e 3B, when analyzing he ac i i y o
he an ioxidan enzymes in he plasma o pa ien s wi h di e en deg ees, he e was a
An ioxidan s 2021,10, 988 9 o 18
s a is ically signi ican dec ease in CAT ac i i y in pa ien s wi h se e e AP compa ed wi h
mild bilia y AP (p< 0.05). Plasma SOD ac i i y was also signi ican ly dec eased when
compa ing pa ien s wi h mild and mode a ely se e e bilia y AP and be ween mild and
se e e bilia y AP pa ien s (p< 0.001, o bo h).
3.3. NMR-Based Me abonomics Analysis o Plasma Samples om AP Pa ien s
To analyze he changes in plasma me abolome ela ed o panc ea ic in lamma ion, we
applied a non a ge ed mul i a ia e analysis. Bo h explo a o y unsupe ised me hod PCA
and supe ised me hod PLS-DA sco es sca e plo s o all se e i y deg ees and analyzed a
he same ime e ealed he signi ican in luence o he in lamma o y p ocess on plasma
me abolome composi ion, which can be obse ed in clus e ing ends o indi idual bilia y
AP g oups.
In Figu e 4a, PCA was applied o es he in e nal da a s uc u e and sea ch o clus e -
ing ends, possible g oup sepa a ion, and ou lie s. Ob ained da a demons a ed clus e ing
acco ding o es ed g oups. O e lap was obse ed be ween con ols and mild bilia y
AP and mode a ely se e e and se e e bilia y AP, indica ing simila i ies o me abolomes.
Addi ionally, da a we e analyzed by PLS-DA, as ep esen ed in Figu e 4b, which is used o
maximize he di e ence be ween g oups.
An ioxidan s 2021, 10, x FOR PEER REVIEW 10 o 19
3.3. NMR-Based Me abonomics Analysis o Plasma Samples om AP Pa ien s
To analyze he changes in plasma me abolome ela ed o panc ea ic in lamma ion,
we applied a non a ge ed mul i a ia e analysis. Bo h explo a o y unsupe ised me hod
PCA and supe ised me hod PLS-DA sco es sca e plo s o all se e i y deg ees and
analyzed a he same ime e ealed he signi ican in luence o he in lamma o y p ocess
on plasma me abolome composi ion, which can be obse ed in clus e ing ends o
indi idual bilia y AP g oups.
In Figu e 4a, PCA was applied o es he in e nal da a s uc u e and sea ch o
clus e ing ends, possible g oup sepa a ion, and ou lie s. Ob ained da a demons a ed
clus e ing acco ding o es ed g oups. O e lap was obse ed be ween con ols and mild
bilia y AP and mode a ely se e e and se e e bilia y AP, indica ing simila i ies o
me abolomes. Addi ionally, da a we e analyzed by PLS-DA, as ep esen ed in Figu e 4b,
which is used o maximize he di e ence be ween g oups.
Figu e 4. Sco es sca e plo s ob ained ia PCA (a) and PLS-DA (b) o 1D cpmg spec a o plasma om heal hy con ol
g oup and bilia y AP pa ien s. Deg ees o bilia y AP se e i y a e indica ed in he legends abo e he plo s.
Pai -wise compa isons be ween bilia y AP se e i y deg ees and he heal hy con ol
g oup we e pe o med (PCA and PLS-DA) o iden i y he me aboli es con ibu ing o
g oup sepa a ion. In PCA sco es, sca e plo clus e ing acco ding o es ed g oups and
p ecise sepa a ion be ween he g oups can be obse ed in Figu e 5a. PLS-DA analysis
u he con i med he g oups’ sepa a ions. A se en old in e nal c oss- alida ion was
applied o assess he explained a iance (R2) and p edica i e powe (Q2) o PLS-DA
models, as ep esen ed in Figu e 5b. Al hough he in e nal alida ion yielded sa is ac o y
model pa ame e s, addi ional alida ion was pe o med ia he pe mu a ion es .
The PLS-DA quali y assessmen pa ame e s, goodness o i o he da a R2, and
p edic i e alue o he model Q2 we e >0.8 in all he cons uc ed models and co obo a e
model eliabili y and hei sui abili y o da a mining, as ep esen ed in Figu e 5c. The
esul s can also be p esen ed as a hea map (Figu e 6) o biologically ele an e ec sizes
(ES > 0.7) [44] conce ning he esul s a ained in he plasma o he g oup o pa ien s wi h
bilia y AP se e i y (mild, mode a ely se e e, o se e e) when compa ed wi h he heal hy
con ol g oup. This ep esen a ion shows ha plasma aline le els had an in e io
di e ence be ween heal hy and mild bilia y AP, bu i was g adually inc eased om
mode a ely se e e and se e e AP. The same happens o isoleucine, h eonine, his idine,
and lipids con en s. When phenylalanine was analyzed, he e was a ma ked inc ease in
heal hy and se e e AP le els. In u n, mala e showed a ma ked inc ease be ween heal hy
and mode a ely se e e AP pa ien s.
Figu e 4.
Sco es sca e plo s ob ained ia PCA (
a
) and PLS-DA (
b
) o 1D cpmg spec a o plasma om heal hy con ol
g oup and bilia y AP pa ien s. Deg ees o bilia y AP se e i y a e indica ed in he legends abo e he plo s.
Pai -wise compa isons be ween bilia y AP se e i y deg ees and he heal hy con ol
g oup we e pe o med (PCA and PLS-DA) o iden i y he me aboli es con ibu ing o g oup
sepa a ion. In PCA sco es, sca e plo clus e ing acco ding o es ed g oups and p ecise
sepa a ion be ween he g oups can be obse ed in Figu e 5a. PLS-DA analysis u he
con i med he g oups’ sepa a ions. A se en old in e nal c oss- alida ion was applied
o assess he explained a iance (R
2
) and p edica i e powe (Q
2
) o PLS-DA models, as
ep esen ed in Figu e 5b. Al hough he in e nal alida ion yielded sa is ac o y model
pa ame e s, addi ional alida ion was pe o med ia he pe mu a ion es .
The PLS-DA quali y assessmen pa ame e s, goodness o i o he da a R
2
, and
p edic i e alue o he model Q
2
we e >0.8 in all he cons uc ed models and co obo a e
model eliabili y and hei sui abili y o da a mining, as ep esen ed in Figu e 5c. The
esul s can also be p esen ed as a hea map (Figu e 6) o biologically ele an e ec sizes
(ES > 0.7) [
44
] conce ning he esul s a ained in he plasma o he g oup o pa ien s
wi h bilia y AP se e i y (mild, mode a ely se e e, o se e e) when compa ed wi h he
heal hy con ol g oup. This ep esen a ion shows ha plasma aline le els had an in e io
di e ence be ween heal hy and mild bilia y AP, bu i was g adually inc eased om
mode a ely se e e and se e e AP. The same happens o isoleucine, h eonine, his idine,
and lipids con en s. When phenylalanine was analyzed, he e was a ma ked inc ease in
heal hy and se e e AP le els. In u n, mala e showed a ma ked inc ease be ween heal hy
and mode a ely se e e AP pa ien s.
An ioxidan s 2021,10, 988 16 o 18
Re e ences
1.
Kaplan, M.; A es, I.; Akpina , M.Y.; Yuksel, M.; Kuzu, U.B.; Kaca , S.; Coskun, O.; Kayace in, E. P edic i e alue o C- eac i e
p o ein/albumin a io in acu e panc ea i is. Hepa obilia y Panc ea . Dis. In . 2017,16, 424–430. [C ossRe ]
2.
Lu, J.D.; Cao, F.; Ding, Y.X.; Wu, Y.D.; Guo, Y.L.; Li, F. Timing, dis ibu ion, and mic obiology o in ec ious complica ions a e
nec o izing panc ea i is. Wo ld J. Gas oen e ol. 2019,25, 5162–5173. [C ossRe ] [PubMed]
3.
Singh, V.K.; Bollen, T.L.; Wu, B.U.; Repas, K.; Mau e , R.; Yu, S.; Mo ele, K.J.; Conwell, D.L.; Banks, P.A. An assessmen o he
se e i y o in e s i ial panc ea i is. Clin. Gas oen e ol. Hepa ol. 2011,9, 1098–1103. [C ossRe ] [PubMed]
4.
Kim, M.-J.; Bae, G.-S.; Jo, I.-J.; Choi, S.-B.; Kim, D.-G.; Jung, H.-J.; Song, H.-J.; Pa k, S.-J. F axinellone inhibi s in lamma o y
cell in il a ion du ing acu e panc ea i is by supp essing in lammasome ac i a ion. In . Immunopha macol.
2019
,69, 169–177.
[C ossRe ] [PubMed]
5.
Hagje , S.; Kuma , N. E alua ion o he BISAP sco ing sys em in p ognos ica ion o acu e panc ea i is—A p ospec i e obse a ional
s udy. In . J. Su g. 2018,54, 76–81. [C ossRe ] [PubMed]
6.
Saman a, J.; Dhaka, N.; Gup a, P.; Singh, A.K.; Yada , T.D.; Gup a, V.; Sinha, S.K.; Kochha , R. Compa a i e s udy o he ou come
be ween alcohol and galls one panc ea i is in a high- olume e ia y ca e cen e . JGH Open
2019
,3, 338–343. [C ossRe ] [PubMed]
7.
Sil a-Vaz, P.; Ab an es, A.M.; Cas elo-B anco, M.; Gou eia, A.; Bo elho, M.F.; T alhão, J.G. Mu ine Models o Acu e Panc ea i is:
A C i ical App aisal o Clinical Rele ance. In . J. Mol. Sci. 2019,20, 2794. [C ossRe ] [PubMed]
8.
Robe s, S.E.; Mo ison-Rees, S.; John, A.; Williams, J.G.; B own, T.H.; Samuel, D.G. The incidence and ae iology o acu e
panc ea i is ac oss Eu ope. Panc ea ology 2017,17, 155–165. [C ossRe ] [PubMed]
9.
Wang, G.J.; Gao, C.F.; Wei, D.; Wang, C.; Ding, S.Q. Acu e panc ea i is: E iology and common pa hogenesis. Wo ld J. Gas oen e ol.
2009,15, 1427–1430. [C ossRe ] [PubMed]
10.
Saluja, A.; Dudeja, V.; Daw a, R.; Sah, R.P. Ea ly In a-Acina E en s in Pa hogenesis o Panc ea i is. Gas oen e ology
2019
,156,
1979–1993. [C ossRe ] [PubMed]
11.
Maye , A.; McMahon, M.; Bowen, M.; Coope , E. C eac i e p o ein: An aid o assessmen and moni o ing o acu e panc ea i is.
J. Clin. Pa hol. 1984,37, 207–211. [C ossRe ] [PubMed]
12.
A abul, M.; Celik, M.; Aslan, O.; To un, S.; Beyazi , Y.; Alpe , E.; Kandemi , A.; Ünsal, B. Hepcidin as a p edic o o disease
se e i y in acu e panc ea i is: A single cen e p ospec i e s udy. Hepa ogas oen e ology 2013,60, 595–600. [PubMed]
13.
Sil a-Vaz, P.; Ab an es, A.M.; Mo gado-Nunes, S.; Cas elo-B anco, M.; Gou eia, A.; Bo elho, M.F.; T alhão, J.G. E alua ion o
P ognos ic Fac o s o Se e i y in Acu e Bilia y Panc ea i is. In . J. Mol. Sci. 2020,21, 4300. [C ossRe ] [PubMed]
14.
Woo, S.M.; Noh, M.H.; Kim, B.G.; Hsing, C.T.; Han, J.S.; Ryu, S.H.; Seo, J.M.; Yoon, H.A.; Jang, J.S.; Choi, S.R.; e al. Compa ison
o se um p ocalci onin wi h Ranson, APACHE-II, Glasgow and Bal haza CT se e i y index sco es in p edic ing se e i y o acu e
panc ea i is. Ko ean J. Gas oen e ol. Taehan Sohwagi Hakhoe Chi 2011,58, 31–37. [C ossRe ] [PubMed]
15.
Wu, B.U.; Johannes, R.S.; Sun, X.; Tabak, Y.; Conwell, D.L.; Banks, P.A. The ea ly p edic ion o mo ali y in acu e panc ea i is: A
la ge popula ion-based s udy. Gu 2008,57, 1698–1703. [C ossRe ] [PubMed]
16.
Mo idi, R.; Du , M.; Wigmo e, S.; Madha an, K.; Ga den, O.; Pa ks, R. Associa ion be ween ea ly sys emic in lamma o y
esponse, se e i y o mul io gan dys unc ion and dea h in acu e panc ea i is. B . J. Su g.
2006
,93, 738–744. [C ossRe ] [PubMed]
17.
Banks, P.A.; Bollen, T.L.; De enis, C.; Gooszen, H.G.; Johnson, C.D.; Sa , M.G.; Tsio os, G.G.; Vege, S.S. Classi ica ion o acu e
panc ea i is—2012: Re ision o he A lan a classi ica ion and de ini ions by in e na ional consensus. Gu
2013
,62, 102–111.
[C ossRe ] [PubMed]
18.
C iddle, D.N. Reac i e oxygen species, Ca(2+) s o es and acu e panc ea i is; a s ep close o he apy? Cell Calcium
2016
,60,
180–189. [C ossRe ] [PubMed]
19.
Pa k, B.K.; Chung, J.B.; Lee, J.H.; Suh, J.H.; Pa k, S.W.; Song, S.Y.; Kim, H.; Kim, K.H.; Kang, J.K. Role o oxygen ee adicals in
pa ien s wi h acu e panc ea i is. Wo ld J. Gas oen e ol. 2003,9, 2266–2269. [C ossRe ] [PubMed]
20.
Closa, D. F ee adicals and acu e panc ea i is: Much ado abou ...some hing. F ee Radic. Res.
2013
,47, 934–940. [C ossRe ]
[PubMed]
21.
Boo h, D.M.; Mukhe jee, R.; Su on, R.; C iddle, D.N. Calcium and eac i e oxygen species in acu e panc ea i is: F iend o oe?
An ioxid. Redox Signal. 2011,15, 2683–2698. [C ossRe ] [PubMed]
22.
Que, R.S.; Cao, L.P.; Ding, G.P.; Hu, J.A.; Mao, K.J.; Wang, G.F. Co ela ion o ni ic oxide and o he ee adicals wi h he
se e i y o acu e panc ea i is and complica ed sys emic in lamma o y esponse synd ome. Panc eas
2010
,39, 536–540. [C ossRe ]
[PubMed]
23.
Vayssie -Taussa , M.; K eps, S.E.; Ad ie, C.; Dall’A a, J.; Ch is iani, D.; Polla, B.S. Mi ochond ial memb ane po en ial: A no el
bioma ke o oxida i e en i onmen al s ess. En i on. Heal h Pe spec . 2002,110, 301–305. [C ossRe ] [PubMed]
24.
T umbeckai e, S.; Kulia iene, I.; Deducho as, O.; Kincius, M.; Baniene, R.; Vi ke y e, S.; Bukauskas, D.; Jansen, E.; Kupcinskas, L.;
Bo u ai e, V.; e al. Expe imen al acu e panc ea i is induces mi ochond ial dys unc ion in a panc eas, kidney and lungs bu no
in li e . Panc ea ology 2013,13, 216–224. [C ossRe ] [PubMed]
25.
Rau, B.; Poch, B.; Gansauge, F.; Baue , A.; Nüssle , A.K.; Ne alainen, T.; Schoenbe g, M.H.; Bege , H.G. Pa hophysiologic ole o
oxygen ee adicals in acu e panc ea i is: Ini ia ing e en o media o o issue damage? Ann. Su g.
2000
,231, 352–360. [C ossRe ]
[PubMed]
26.
Gu, W.; Tong, Z. Clinical Applica ion o Me abolomics in Panc ea ic Diseases: A Mini-Re iew. Lab. Med.
2020
,51, 116–121.
[C ossRe ] [PubMed]

An ioxidan s 2021,10, 988 17 o 18
27.
Villaseno , A.; Kin oss, J.M.; Li, J.V.; Penney, N.; Ba on, R.H.; Nicholson, J.K.; Da zi, A.; Ba bas, C.; Holmes, E. 1H NMR global
me abolic pheno yping o acu e panc ea i is in he eme gency uni . J. P o eome Res. 2014,13, 5362–5375. [C ossRe ] [PubMed]
28.
Lusczek, E.R.; Paulo, J.A.; Sal zman, J.R.; Kadiyala, V.; Banks, P.A.; Beilman, G.; Conwell, D.L. U ina y 1H-NMR me abolomics
can dis inguish panc ea i is pa ien s om heal hy con ols. JOP J. Panc eas 2013,14, 161–170.
29.
Xu, H.; Zhang, L.; Kang, H.; Zhang, J.; Liu, J.; Liu, S. Se um Me abonomics o Mild Acu e Panc ea i is. J. Clin. Lab. Anal.
2016
,30,
990–998. [C ossRe ] [PubMed]
30.
Xiao, H.; Huang, J.-h.; Zhang, X.-w.; Ahmed, R.; Xie, Q.-l.; Li, B.; Zhu, Y.-m.; Cai, X.; Peng, Q.-h.; Qin, Y.-h. Iden i ica ion o
po en ial diagnos ic bioma ke s o acu e panc ea i is by se um me abolomic p o iles. Panc ea ology
2017
,17, 543–549. [C ossRe ]
[PubMed]
31.
Huang, J.H.; He, D.; Chen, L.; Dong, C.Y.; Zhang, S.H.; Qin, Y.H.; Yu, R.; Ahmed, R.; Kuang, J.J.; Zhang, X.W. GC-MS based
me abolomics s a egy o dis inguish h ee ypes o acu e panc ea i is. Panc ea ology 2019,19, 630–637. [C ossRe ] [PubMed]
32.
Wei z, G.; Woi alla, J.; Wellhöne , P.; Schmid , K.J.; Büning, J.; Felle mann, K. Como bidi y in acu e panc ea i is ela es o o gan
ailu e bu no o local complica ions. Z. Gas oen e ol. 2016,54, 226–230. [C ossRe ] [PubMed]
33.
B usselae s, N.; Lage g en, J. The Cha lson Como bidi y Index in Regis y-based Resea ch. Me hods In . Med.
2017
,56, 401–406.
[PubMed]
34.
Dias, T.R.; Al es, M.G.; Be na dino, R.L.; Ma ins, A.D.; Mo ei a, A.C.; Sil a, J.; Ba os, A.; Sousa, M.; Sil a, B.M.; Oli ei a, P.F.
Dose-dependen e ec s o ca eine in human Se oli cells me abolism and oxida i e p o ile: Rele ance o male e ili y. Toxicology
2015,328, 12–20. [C ossRe ] [PubMed]
35.
Oli ei a, P.F.; Tomas, G.D.; Dias, T.R.; Ma ins, A.D.; Ra o, L.; Al es, M.G.; Sil a, B.M. Whi e ea consump ion es o es spe m
quali y in p ediabe ic a s p e en ing es icula oxida i e damage. Rep od. Biomed. Online
2015
,31, 544–556. [C ossRe ] [PubMed]
36.
Bake , M.A.; Ce niglia, G.J.; Zaman, A. Mic o i e pla e assay o he measu emen o glu a hione and glu a hione disul ide in
la ge numbe s o biological samples. Anal. Biochem. 1990,190, 360–365. [C ossRe ]
37.
Ogun ibeju, O.O.; Meye , S.; Aboua, Y.G.; Goboza, M. Hypoxis heme ocallidea Signi ican ly Reduced Hype glycaemia and
Hype glycaemic-Induced Oxida i e S ess in he Li e and Kidney Tissues o S ep ozo ocin-Induced Diabe ic Male Wis a Ra s.
E id. Based Complemen a y Al e n. Med. 2016,2016, 8934362. [C ossRe ] [PubMed]
38.
Al es, M.G.; Oli ei a, P.J.; Ca alho, R.A. Subs a e selec ion in hea s subjec ed o ischemia/ epe usion: Role o ca dioplegic
solu ions and gende . NMR Biomed. 2011,24, 1029–1037. [C ossRe ] [PubMed]
39.
Wisha , D.S.; Feunang, Y.D.; Ma cu, A.; Guo, A.C.; Liang, K.; Vazquez-F esno, R.; Sajed, T.; Johnson, D.; Li, C.; Ka u, N.; e al.
HMDB 4.0: The human me abolome da abase o 2018. Nucleic Acids Res. 2018,46, D608–D617. [C ossRe ] [PubMed]
40.
Ja ak, I.; Ca ola, J.; Ba os, A.S.; Gil, A.M.; Pe ei a, M.L.; Co o, M.L.; Dua e, I.F. F om he Co e : Me abolism Modula ion
in Di e en O gans by Sil e Nanopa icles: An NMR Me abolomics S udy o a Mouse Model. Toxicol. Sci.
2017
,159, 422–435.
[C ossRe ]
41.
Sa o ani, F.; Tomasi, G.; Engelsen, S.B. icoshi : A e sa ile ool o he apid alignmen o 1D NMR spec a. J. Magn. Reson.
2010
,
202, 190–202. [C ossRe ] [PubMed]
42.
Die e le, F.; Ross, A.; Schlo e beck, G.; Senn, H. P obabilis ic quo ien no maliza ion as obus me hod o accoun o dilu ion o
complex biological mix u es. Applica ion in 1H NMR me abonomics. Anal. Chem. 2006,78, 4281–4290. [C ossRe ] [PubMed]
43.
T iba, M.N.; Le Moyec, L.; Ama hieu, R.; Goossens, C.; Bouchemal, N.; Nahon, P.; Ru ledge, D.N.; Sa a in, P. PLS/OPLS models
in me abolomics: The impac o pe mu a ion o da ase ows on he K- old c oss- alida ion quali y pa ame e s. Mol. Biosys .
2015,11, 13–19. [C ossRe ] [PubMed]
44.
Be ben, L.; Se eika, S.M.; Engbe g, S. E ec size es ima ion: Me hods and examples. In . J. Nu s. S ud.
2012
,49, 1039–1047.
[C ossRe ] [PubMed]
45.
an Dijk, S.M.; Hallensleben, N.D.; an San oo , H.C.; Fockens, P.; an Goo , H.; B uno, M.J.; Besselink, M.G. Acu e panc ea i is:
Recen ad ances h ough andomised ials. Gu 2017,66, 2024–2032. [C ossRe ] [PubMed]
46.
Sil a-Vaz, P.; Ab an es, A.M.; Cas elo-B anco, M.; Gou eia, A.; Bo elho, M.F.; T alhao, J.G. Mul i ac o ial Sco es and Bioma ke s
o P ognosis o Acu e Panc ea i is: Applica ions o Resea ch and P ac ice. In . J. Mol. Sci. 2020,21, 338. [C ossRe ] [PubMed]
47. Ca w igh , S.L.; Knudson, M.P. E alua ion o acu e abdominal pain in adul s. Am. Fam. Physician 2008,77, 971–978. [PubMed]
48.
Li, J.; Zhu, S.F.; Zhao, X.L.; Liu, Y.X.; Wan, M.H.; Guo, H.; Liu, Y.L.; Gong, H.L.; Chen, G.Y.; Tang, W.F. Me abolomic p o iles
illumina e he e icacy o Chinese he bal Da-Cheng-Qi decoc ion on acu e panc ea i is in a s. Panc ea ology
2015
,15, 337–343.
[C ossRe ] [PubMed]
49.
Zhao, X.; Chen, D.Z.; Lang, R.; Jin, Z.K.; Fan, H.; Wu, T.M.; Li, X.L.; He, Q. Enhanced eco e y in he managemen o mild
galls one panc ea i is: A p ospec i e coho s udy. Su g. Today 2013,43, 643–647. [C ossRe ] [PubMed]
50.
Khanna, A.K.; Mehe , S.; P akash, S.; Tiwa y, S.K.; Singh, U.; S i as a a, A.; Dixi , V. Compa ison o Ranson, Glasgow, MOSS,
SIRS, BISAP, APACHE-II, CTSI Sco es, IL-6, CRP, and p ocalci onin in p edic ing se e i y, o gan ailu e, panc ea ic nec osis, and
mo ali y in acu e panc ea i is. HPB Su g. 2013,2013, 367581. [C ossRe ] [PubMed]
51.
Al-Nawas, B.; K amme , I.; Shah, P.M. P ocalci onin in diagnosis o se e e in ec ions. Eu . J. Med. Res.
1996
,1, 331–333. [PubMed]
52.
Gu, L.; Ma, X.; Wang, L.; Li, H.; Chen, L.; Li, X.; Zhang, Y.; Xie, Y.; Zhang, X. P ognos ic alue o a sys emic in lamma o y esponse
index in me as a ic enal cell ca cinoma and cons uc ion o a p edic i e model. Onco a ge
2017
,8, 52094–52103. [C ossRe ]
[PubMed]
An ioxidan s 2021,10, 988 18 o 18
53. Chen, L.; Kong, X.; Wang, Z.; Wang, X.; Fang, Y.; Wang, J. P e ea men Sys emic In lamma ion Response Index in Pa ien s wi h
B eas Cance T ea ed wi h Neoadju an Chemo he apy as a Use ul P ognos ic Indica o . Cance Manag. Res.
2020
,12, 1543–1567.
[C ossRe ] [PubMed]
54.
Ca doso, F.S.; Rica do, L.B.; Oli ei a, A.M.; Ho a, D.V.; Papoila, A.L.; Deus, J.R.; Canena, J. C-Reac i e P o ein a 24 Hou s a e
Hospi al Admission may ha e Rele an P ognos ic Accu acy in Acu e Panc ea i is: A Re ospec i e Coho S udy. GE Po . J.
Gas oen e ol. 2015,22, 198–203. [C ossRe ] [PubMed]
55.
Kulaksiz, H.; Fein, E.; Redecke , P.; S emmel, W.; Adle , G.; Ce in, Y. Panc ea ic b-cells exp ess hepcidin, an i on-up ake egula o y
pep ide. J. Endoc inol. 2008,197, 241–250. [C ossRe ] [PubMed]
56.
Babi , J.L.; Huang, F.W.; W igh ing, D.M.; Xia, Y.; Sidis, Y.; Samad, T.A.; Campagna, J.A.; Chung, R.T.; Schneye , A.L.; Wool ,
C.J. Bone mo phogene ic p o ein signaling by hemoju elin egula es hepcidin exp ession. Na . Gene .
2006
,38, 531. [C ossRe ]
[PubMed]
57. Pe ez, S.; Pe eda, J.; Saba e , L.; Sas e, J. Redox signaling in acu e panc ea i is. Redox Biol. 2015,5, 1–14. [C ossRe ] [PubMed]
58.
Song, J.Y.; Lim, J.W.; Kim, H.; Mo io, T.; Kim, K.H. Oxida i e s ess induces nuclea loss o DNA epai p o eins Ku70 and Ku80
and apop osis in panc ea ic acina AR42J cells. J. Biol. Chem. 2003,278, 36676–36687. [C ossRe ] [PubMed]
59.
Abu-Hilal, M.; McPhail, M.J.; Ma chand, L.; Johnson, C.D. Malondialdehyde and supe oxide dismu ase as po en ial ma ke s o
se e i y in acu e panc ea i is. JOP J. Panc eas 2006,7, 185–192.
60.
Ma ek, G.; ´
Sciskalska, M.; G zebieniak, Z.; Milne owicz, H. Dec eases in Pa aoxonase-1 Ac i i ies P omo e a P o-in lamma o y
E ec o Lipids Pe oxida ion P oduc s in Non-smoking and Smoking Pa ien s wi h Acu e Panc ea i is. In . J. Med. Sci.
2018
,15,
1619–1630. [C ossRe ] [PubMed]
61.
Sajewicz, W.; Milne owicz, S.; Nabzdyk, S. Blood plasma an ioxidan de ense in pa ien s wi h panc ea i is. Panc eas
2006
,32,
139–144. [C ossRe ] [PubMed]
62.
Ab eu, F.F.; Souza, A.C.A.; Teixei a, S.A.; Soa es, A.G.; Teixei a, D.F.; Soa es, R.C.; San ana, M.T.; Lau on San os, S.; Cos a, S.K.P.;
Musca á, M.N.; e al. Elucida ing he ole o oxida i e s ess in he he apeu ic e ec o u in on expe imen al acu e panc ea i is.
F ee Radic. Res. 2016,50, 1350–1360. [C ossRe ] [PubMed]
63.
Bopanna, S.; Nayak, B.; P akash, S.; Shalima ; Mahapa a, S.J.; Ga g, P.K. Inc eased oxida i e s ess and de icien an ioxidan
le els may be in ol ed in he pa hogenesis o idiopa hic ecu en acu e panc ea i is. Panc ea ology
2017
,17, 529–533. [C ossRe ]
[PubMed]
64.
Ja ak, I.; Almeida, S.; Ca alho, R.A.; Sousa, M.; Ba os, A.; Al es, M.G.; Oli ei a, P.F. Senescence and declining ep oduc i e
po en ial: Insigh in o molecula mechanisms h ough es icula me abolomics. Biochim. Biophys. Ac a Mol. Basis Dis.
2018
,1864,
3388–3396. [C ossRe ] [PubMed]
65.
Wang, J.; Ma, C.; Liao, Z.; Tian, B.; Lu, J.P. S udy on ch onic panc ea i is and panc ea ic cance using MRS and panc ea ic juice
samples. Wo ld J. Gas oen e ol. 2011,17, 2126–2130. [C ossRe ] [PubMed]
66.
Jeu nink, S.M.; Nijs, M.M.; P ins, H.A.; G e ing, J.P.; Sie sema, P.D. An ioxidan s as a ea men o acu e panc ea i is: A
me a-analysis. Panc ea ology 2015,15, 203–208. [C ossRe ] [PubMed]
67. Kim, H. Glu amine as an immunonu ien . Yonsei Med. J. 2011,52, 892–897. [C ossRe ] [PubMed]
68.
G imble, R.F. The In e ac ion Be ween Nu i ion and In lamma o y S ess Th oughou he Li e Cycle. In Nu ien s, S ess and
Medical Diso de s; Yehuda, S., Mos o sky, D.I., Eds.; Humana P ess: To owa, NJ, USA, 2005; pp. 387–424.
69.
Tang, M.; Hu, G.; Zhao, Y.; Su, M.; Wang, Y.; Jia, W.; Qiu, Y.; Liu, G.; Wang, X. A se um me abolomic in es iga ion on lipop o ein
lipase-de icien mice wi h hype lipidemic panc ea i is using gas ch oma og aphy/mass spec ome y. Biomed. Rep.
2013
,1,
469–473. [C ossRe ] [PubMed]
70.
Dong, Y.W.; Jiang, W.D.; Liu, Y.; Wu, P.; Jiang, J.; Kuang, S.Y.; Tang, L.; Tang, W.N.; Zhang, Y.A.; Zhou, X.Q.; e al. Th eonine
de iciency dec eased in es inal immuni y and agg a a ed in lamma ion associa ed wi h NF-kappaB and a ge o apamycin
signalling pa hways in ju enile g ass ca p (C enopha yngodon idella) a e in ec ion wi h Ae omonas hyd ophila. B . J. Nu .
2017,118, 92–108. [C ossRe ] [PubMed]
71.
Huang, S.S.; Lin, J.Y.; Chen, W.S.; Liu, M.H.; Cheng, C.W.; Cheng, M.L.; Wang, C.H. Phenylalanine- and leucine-de ined me abolic
ypes iden i y high mo ali y isk in pa ien s wi h se e e in ec ion. In . J. In ec . Dis. 2019,85, 143–149. [C ossRe ]
72.
Biczo, G.; Vegh, E.T.; Shalbue a, N.; Ma enino a, O.A.; Elpe in, J.; Lo shaw, E.; G e le , S.; Lugea, A.; Malla, S.R.; Daw-
son, D.; e al. Mi ochond ial Dys unc ion, Th ough Impai ed Au ophagy, Leads o Endoplasmic Re iculum S ess, De egula ed
Lipid Me abolism, and Panc ea i is in Animal Models. Gas oen e ology 2018,154, 689–703. [C ossRe ] [PubMed]
73.
Szymanska, E.; F yden ang, K.; Picke ing, D.S.; K in el, C.; Nielsen, B.; Kooshki, A.; Zacha iassen, L.G.; Olsen, L.; Kas up, J.S.;
Johansen, T.N. S udies on A yl-Subs i u ed Phenylalanines: Syn hesis, Ac i i y, and Di e en Binding Modes a AMPA Recep o s.
J. Med. Chem. 2016,59, 448–461. [C ossRe ] [PubMed]